{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:35:24Z","timestamp":1793208924897,"version":"4.5.0"},"reference-count":45,"publisher":"BMJ","issue":"11","funder":[{"name":"this work was supported by the World Health Organization and UNITAID.","id":[{"id":"https:\/\/ror.org\/01f80g185","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2018,4,5]]},"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Extrahepatic manifestations of HCV are responsible for morbidity and mortality in many chronically infected patients. New, interferon-free antiviral treatment regimens, which present the opportunity to treat all HCV-infected patients, call for a better understanding of the benefits of treating non-cirrhotic chronically infected individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review was conducted. Identified studies from targeted database searches on Embase and Medline were screened. The methodological quality of the included publications was evaluated. Random-effect model meta-analyses were performed. Strength of evidence was evaluated using the Grading of Recommendations Assessment, Development and Evaluation system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data were extracted from a total of 48 identified studies. Achieving sustained virological response (SVR) was associated with reduced extrahepatic mortality (vs no SVR, OR 0.44 (95%\u2009CI 0.28 to 0.67)). SVR was associated with higher complete remissions in patients with cryoglobulinemia vasculitis (OR 20.76 (6.73 to 64.05)) and a higher objective response in those with malignant B-cell lymphoproliferative diseases (OR 6.49 (2.02 to 20.85)). Achieving SVR was also associated with reduced insulin resistance at follow-up (OR 0.42 (0.33 to 0.53)) and a significant protective effect on the incidence of diabetes (OR 0.34 (0.21 to 0.56)). Lack of randomised data comparing SVR versus non-SVR patients for the relevant extrahepatic indications attenuated these analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Antiviral therapy can reduce extrahepatic manifestations related to HCV when SVR is achieved. Higher quality data, and reporting over longer follow-up periods, will be required to thoroughly explore comprehensive HCV treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2018-316234","type":"journal-article","created":{"date-parts":[[2018,4,27]],"date-time":"2018-04-27T12:21:12Z","timestamp":1524831672000},"page":"2025-2034","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":115,"title":["Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis"],"prefix":"10.1136","volume":"67","author":[{"given":"Patrice","family":"Cacoub","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9s, UPMC Univ Paris, Paris, France"},{"name":"Inflammation\u2013Immunopathology\u2013Biotherapy Department, DHU i2B, Paris, France"},{"name":"INSERM, UMRS 959, Paris, France"},{"name":"Department of Internal Medicine and Clinical Immunology, AP-HP, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Claire","family":"Desbois","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s, UPMC Univ Paris, Paris, France"},{"name":"Inflammation\u2013Immunopathology\u2013Biotherapy Department, DHU i2B, Paris, France"},{"name":"INSERM, UMRS 959, Paris, France"},{"name":"Department of Internal Medicine and Clinical Immunology, AP-HP, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cloe","family":"Comarmond","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s, UPMC Univ Paris, Paris, France"},{"name":"Inflammation\u2013Immunopathology\u2013Biotherapy Department, DHU i2B, Paris, France"},{"name":"INSERM, UMRS 959, Paris, France"},{"name":"Department of Internal Medicine and Clinical Immunology, AP-HP, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Saadoun","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s, UPMC Univ Paris, Paris, France"},{"name":"Inflammation\u2013Immunopathology\u2013Biotherapy Department, DHU i2B, Paris, France"},{"name":"INSERM, UMRS 959, Paris, France"},{"name":"Department of Internal Medicine and Clinical Immunology, AP-HP, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,4,27]]},"reference":[{"key":"2025090712594100000_67.11.2025.1","unstructured":"WHO. Global hepatitis C infection report. 2017 http:\/\/www.who.int\/hepatitis\/publications\/global-hepatitis-report2017\/en\/."},{"key":"2025090712594100000_67.11.2025.2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2523562"},{"key":"2025090712594100000_67.11.2025.3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","article-title":"The global burden of hepatitis C","volume":"29","author":"Lavanchy","year":"2009","journal-title":"Liver International"},{"key":"2025090712594100000_67.11.2025.4","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D"},{"key":"2025090712594100000_67.11.2025.5","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir306"},{"key":"2025090712594100000_67.11.2025.6","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis385"},{"key":"2025090712594100000_67.11.2025.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2012.09.009"},{"key":"2025090712594100000_67.11.2025.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2010.09.014"},{"key":"2025090712594100000_67.11.2025.9","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23002"},{"key":"2025090712594100000_67.11.2025.10","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i17.2467"},{"key":"2025090712594100000_67.11.2025.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.03.004"},{"key":"2025090712594100000_67.11.2025.12","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26892"},{"key":"2025090712594100000_67.11.2025.13","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.autrev.2017.03.004","article-title":"International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement","volume":"16","author":"Zignego","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2025090712594100000_67.11.2025.14","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i13.3410"},{"key":"2025090712594100000_67.11.2025.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2007.06.022"},{"key":"2025090712594100000_67.11.2025.16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700"},{"key":"2025090712594100000_67.11.2025.17","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.gastro.2016.09.009","article-title":"Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications","volume":"152","author":"Nahon","year":"2017","journal-title":"Gastroenterology"},{"key":"2025090712594100000_67.11.2025.18","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308163"},{"key":"2025090712594100000_67.11.2025.19","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nrgastro.2016.176","article-title":"Global epidemiology and burden of HCV infection and HCV-related disease","volume":"14","author":"Thrift","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025090712594100000_67.11.2025.20","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40121-016-0134-x","article-title":"Value of treating all stages of chronic hepatitis C: a comprehensive review of clinical and economic evidence","volume":"5","author":"Nu\u00f1o Solin\u00eds","year":"2016","journal-title":"Infect Dis Ther"},{"key":"2025090712594100000_67.11.2025.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2015.02.017"},{"key":"2025090712594100000_67.11.2025.22","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.1.101"},{"key":"2025090712594100000_67.11.2025.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.02.011"},{"key":"2025090712594100000_67.11.2025.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.04.021"},{"key":"2025090712594100000_67.11.2025.25","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/bjc.2017.345","article-title":"Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations","volume":"117","author":"Visco","year":"2017","journal-title":"Br J Cancer"},{"key":"2025090712594100000_67.11.2025.26","doi-asserted-by":"crossref","first-page":"31110","DOI":"10.1002\/ijc.31110","article-title":"Clinicopathologic characteristics and outcomes of transformed diffuse large B-cell lymphoma in hepatitis C virus-infected patients","volume":"142","author":"Hosry","year":"2018","journal-title":"Int J Cancer"},{"key":"2025090712594100000_67.11.2025.27","first-page":"411","article-title":"The oncologic burden of hepatitis C virus infection: a clinical perspective","volume":"67","author":"Torres","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2025090712594100000_67.11.2025.28","first-page":"8","article-title":"Extrahepatic manifestations of chronic hepatitis C virus infection","volume":"15","author":"Cacoub","year":"2014","journal-title":"Dig Liver Dis"},{"key":"2025090712594100000_67.11.2025.29","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1053\/j.gastro.2016.02.039","article-title":"Extrahepatic manifestations of hepatitis C: a meta-analysis of\u00a0prevalence, quality of life, and economic burden","volume":"150","author":"Younossi","year":"2016","journal-title":"Gastroenterology"},{"key":"2025090712594100000_67.11.2025.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.08.006"},{"key":"2025090712594100000_67.11.2025.31","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.3748\/wjg.v23.i9.1697","article-title":"Diabetes mellitus, insulin resistance and hepatitis C virus infection: a contemporary review","volume":"23","author":"Desbois","year":"2017","journal-title":"World J Gastroenterol"},{"key":"2025090712594100000_67.11.2025.32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/liv.13282","article-title":"Impact of hepatitis C virus therapy on metabolism and public health","volume":"37 Suppl 1","author":"Shiffman","year":"2017","journal-title":"Liver Int"},{"key":"2025090712594100000_67.11.2025.33","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jhep.2017.02.010","article-title":"Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection","volume":"66","author":"Ramos-Casals","year":"2017","journal-title":"J Hepatol"},{"key":"2025090712594100000_67.11.2025.34","first-page":"29086","article-title":"Aasld guidelines for the treatment of hepatocellular carcinoma","volume":"28","author":"Heimbach","year":"2017","journal-title":"Hepatology"},{"key":"2025090712594100000_67.11.2025.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.09.001"},{"key":"2025090712594100000_67.11.2025.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.08.003"},{"key":"2025090712594100000_67.11.2025.37","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.5"},{"key":"2025090712594100000_67.11.2025.38","first-page":"30246","article-title":"Direct antiviral agents (DAAs)\u2014a new age in the treatment of hepatitis C virus infection","volume":"10","author":"Spengler","year":"2017","journal-title":"Pharmacol Ther"},{"key":"2025090712594100000_67.11.2025.39","doi-asserted-by":"crossref","unstructured":"Jakobsen JC , Nielsen EE , Feinberg J , et al . Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev 2017;18.","DOI":"10.1002\/14651858.CD012143.pub2"},{"key":"2025090712594100000_67.11.2025.40","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/hep.28753","article-title":"Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia","volume":"64","author":"Gragnani","year":"2016","journal-title":"Hepatology"},{"key":"2025090712594100000_67.11.2025.41","doi-asserted-by":"crossref","first-page":"017","DOI":"10.1186\/s13075-017-1280-6","article-title":"Direct-acting antiviral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia: a single-centre experience","volume":"19","author":"Lauletta","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025090712594100000_67.11.2025.42","doi-asserted-by":"crossref","first-page":"14382","DOI":"10.1111\/apt.14382","article-title":"Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France","volume":"47","author":"Cacoub","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2025090712594100000_67.11.2025.43","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.gaceta.2016.06.005","article-title":"[Care costs and activity in the last three months of life of cancer patients who died in the Basque Country (Spain)]","volume":"31","author":"Nu\u00f1o-Solin\u00eds","year":"2017","journal-title":"Gac Sanit"},{"key":"2025090712594100000_67.11.2025.44","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s40471-017-0108-x","article-title":"Hepatitis c: review of the epidemiology, clinical care, and continued challenges in the direct acting antiviral era","volume":"4","author":"Millman","year":"2017","journal-title":"Curr Epidemiol Rep"},{"key":"2025090712594100000_67.11.2025.45","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2016.1161023"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2018-316234","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T19:59:53Z","timestamp":1757275193000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2018-316234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,27]]},"references-count":45,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,10,8]]},"published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1136\/gutjnl-2018-316234"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2018-316234","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733126442.793545424","asserted-by":"object"}]},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,27]]}}}